Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs

scientific article published on 15 April 2010

Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.4161/CC.9.8.11487
P932PMC publication ID3781180
P698PubMed publication ID20372086
P5875ResearchGate publication ID43050375

P50authorAlberto M MartelliQ56922777
Jörg BaeseckeQ69033710
Ferdinando NicolettiQ84521195
Linda S SteelmanQ114723345
Franca StivalaQ114723350
Stephen L AbramsQ123366731
William H ChappellQ123366743
Massimo LibraQ37842996
Marco DoniaQ40146733
James A. McCubreyQ42317570
P2093author name stringJohn G Shelton
P2860cites workPseudo-DNA damage response in senescent cellsQ28583844
ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostateQ33415974
New agents for the treatment of acute myeloid leukemiaQ36413300
Program-like aging and mitochondria: instead of random damage by free radicalsQ36988252
Targeting prostate cancer based on signal transduction and cell cycle pathways.Q36995054
PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospectsQ37032524
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Q37109225
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistanceQ46441674
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanismQ46666883
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cellsQ46956224
Genomic instability en route to and from cancer stem cells.Q53312262
Differential effects of retroviral long terminal repeats on interleukin-3 gene expression and autocrine transformation.Q53440045
Resist or die: FOXO transcription factors determine the cellular response to chemotherapy.Q53446661
MNK, EIF4E and targeting translation for therapy.Q53499743
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretionQ56995355
Abrogation of factor-dependence in two IL-3-dependent cell lines can occur by two distinct mechanismsQ69738450
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromesQ80599609
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.Q37109227
Cancer stem cell and cancer stemloids: from biology to therapyQ37111467
The tumor suppressor p53: cancer and agingQ37138969
Cancer stem cells and survival pathwaysQ37141755
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approachesQ37192606
Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmacologic rejuvenation of aging stem cellsQ37253119
Targeting the leukemic stem cell: the Holy Grail of leukemia therapyQ37272565
Aging: ROS or TOR.Q37312907
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.Q37331720
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemiaQ37331742
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitorsQ37355543
Targeting mTOR with rapamycin: one dose does not fit allQ37409171
Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursorsQ37554117
Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A.Q39783675
Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescenceQ39845659
Rapamycin decelerates cellular senescenceQ39846812
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.Q39869731
Growth stimulation leads to cellular senescence when the cell cycle is blockedQ39925937
Phosphoinositide 3-kinase signaling overrides a G2 phase arrest checkpoint and promotes aberrant cell cycling and death of hematopoietic cells after DNA damage.Q39943580
GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphomaQ39943592
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.Q39991616
The role of the PTEN/AKT Pathway in NOTCH1-induced leukemiaQ39991646
Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapyQ40077070
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blastsQ40184405
Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.Q40287051
P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells.Q40790669
Malignant transformation induced by cytokine genes: a comparison of the abilities of germline and mutated interleukin 3 genes to transform hematopoietic cells by transcriptional and posttranscriptional mechanismsQ41207196
Synergy between AUUUA motif disruption and enhancer insertion results in autocrine transformation of interleukin-3-dependent hematopoietic cellsQ41282247
The CML stem cell: evolution of the progenitorQ42135962
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemiaQ42742064
Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.Q44419395
At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence.Q45995695
Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration.Q46008332
Translational control and cancer therapyQ46372387
Cancer and aging: more puzzles, more promises?Q46417167
P433issue8
P921main subjectchemotherapyQ974135
apoptotic processQ14599311
P1104number of pages10
P304page(s)1629-1638
P577publication date2010-04-15
P1433published inCell CycleQ1254166
P1476titleDominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs
P478volume9

Reverse relations

cites work (P2860)
Q27686983Advances in targeting signal transduction pathways
Q36351612Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.
Q92645527Clinicopathological significance of ribosomal protein S6 kinase A6 in lung squamous cell carcinoma: an immunohistochemical and RNA-seq study
Q35640301Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells
Q36189476Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization
Q92208308Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway
Q36556350Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine
Q39182610Effect of Chaihushugan San on expression of the Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase pathway in the hippocampi of perimenopausal rats induced by immobilization stress
Q37192616Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy
Q35556981Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells
Q39116774Lys63-linked polyubiquitination of BRAF at lysine 578 is required for BRAF-mediated signaling.
Q36304116MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2.
Q36862768Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response
Q35679353Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
Q36477469Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Q37865381Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Q39441370Selective Targeting of RSK Isoforms in Cancer
Q31114420Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data
Q36179524Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.
Q47110143Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells
Q37618829The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system
Q37837732Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.